Lonza Strengthens Advanced Synthesis Offering
By fully integrating support for ADC technologies into its Advanced Synthesis portfolio, Lonza is now able to offer phase-appropriate CDMO support for bioconjugates from discovery through clinical supply.
Global CDMO, Lonza, has announced that its Advanced Synthesis service now fully encompasses antibody-drug conjugates (ADCs) and other bioconjugates for phase-appropriate support from discovery through development. This expanded offering was revealed by the company in a Feb. 19, 2026 press release (1).
Acquired through the 2023 acquisition of Synaffix (2), the company’s Advanced Synthesis Portfolio boosts the efficacy and tolerability of ADCs through validated, site-specific technologies. This includes the proprietary GlycoConnect platform for site-specific antibody conjugation via biocatalytic glycan remodeling; HydraSpace, a highly polar spacer that optimizes pharmacokinetics and reduces off-target toxicity; and a growing portfolio of toxSYN linker-payloads.
The technologies have now been expanded to include dual-payload ADC technology, allowing precise attachment of two cytotoxic agents on a single antibody to address tumor heterogeneity and overcome resistance mechanisms. Through the broader offering, Lonza’s clients can now gain access to innovative ADC design within a fully integrated, scalable CDMO framework from discovery through to clinical supply.
Complementing the platform integration, Lonza's Oss, Netherlands facility has received investment to enable wider R&D for ADCs and emerging bioconjugates, such as antibody-oligonucleotide conjugates, targeted lipid nanoparticles, and protein–protein conjugates. The site now offers rapid small-scale prototyping alongside scale-up for pilot toxicology material, with integrated on-site process and analytical development.
“Our recent advancements across Advanced Synthesis strengthen the support we provide to drug developers active in the field of ADCs and other bioconjugates,” said Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis at Lonza, in the press release (1). “The expansion of the Oss site further reinforces Lonza’s global bioconjugate development and manufacturing network and underscores our dedication to continuously improving our offering and expertise in line with evolving customer and market needs.”
The announcement arrives amid a booming ADC market, with some analysts projecting the sector will exceed USD 30 billion by 2033, driven by rising cancer prevalence and demand for targeted therapies with lower toxicity (3). Lonza's upgrades strengthen its competitive position, tapping into burgeoning pipelines and biotech demands for comprehensive CDMO services despite funding hurdles and bolsters the company’s small-molecule and hybrid expertise.
References
Lonza. Lonza Strengthens Advanced Synthesis Capabilities to Lead Bioconjugates Innovation and Development. Press release, Feb. 19, 2026.
Lonza. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering. Press Release, June 1, 2023.
Data Intelligence. Antibody-Drug Conjugates (ADC) Market — Industry Trends and Outlook. Market Research Report, July 16, 2025.